Table 2.
Clinical features of head and neck squamous cell carcinoma patients and association to sialidase NEU3 mRNA level in lymph node metastasis
| TNM category | No. of patients | T/N ratio | P‐value | |
|---|---|---|---|---|
| NEU3 | ||||
| Total | 30 | 6.67 ± 6.79 | ||
| Stage | I–II | 6 | 2.96 ± 4.04 | 0.055 |
| III–IV | 24 | 6.88 ± 6.82 | ||
| Tumor size | T1–T2 | 12 | 7.36 ± 7.88 | 0.580 |
| T3–T4 | 17 | 6.06 ± 6.53 | ||
| Lymph node metastasis | N0 | 11 | 2.81 ± 2.89 | 0.019a |
| N1–N3 | 19 | 7.79 ± 7.17 | ||
| NEU1 | ||||
| Total | 30 | 3.11 ± 3.94 | ||
| Stage | I–II | 6 | 2.61 ± 2.59 | 0.470 |
| III–IV | 24 | 3.23 ± 4.20 | ||
| Tumor size | T1–T2 | 12 | 2.17 ± 2.03 | 0.190 |
| T3–T4 | 17 | 3.16 ± 4.05 | ||
| Lymph node metastasis | N0 | 11 | 3.01 ± 2.84 | 0.490 |
| N1–N3 | 19 | 3.16 ± 4.45 | ||
a
Significant difference was observed between lymph node metastasis N0 and N1–N3 in sialidase NEU3 mRNA level.